Fidelity Investments’s HTG Molecular Diagnostics, Inc. Common Stock HTGM Stock Holding History

Fidelity Investments’s Portfolio HTGM Stock Details HTGM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-14,961	Closed	-$1.83M	–	4400
2019 Q3	$1.83M	Hold	14,961	–	–	﹤0.01%	2287
2019 Q2	$4.47M	Sell	14,961 -3,388	-18%	-$1.41M	﹤0.01%	2125
2019 Q1	$8.26M	Sell	18,349 -1,695	-8%	-$742K	﹤0.01%	1928
2018 Q4	$9.16M	Buy	20,044 +110	+0.6%	+$68.2K	﹤0.01%	1832
2018 Q3	$18.1M	Buy	19,934 +556	+3%	+$367K	﹤0.01%	1717
2018 Q2	$11.4M	Buy	19,378 +154	+0.8%	+$100K	﹤0.01%	1910
2018 Q1	$12.5M	Buy	19,224 +15,483	+414%	+$11.6M	﹤0.01%	1896
2017 Q4	$1.37M	Hold	3,741	–	–	﹤0.01%	2411
2017 Q3	$1.15M	Hold	3,741	–	–	﹤0.01%	2403
2017 Q2	$1.79M	Hold	3,741	–	–	﹤0.01%	2359
2017 Q1	$4.66M	Hold	3,741	–	–	﹤0.01%	2187
2016 Q4	$1.51M	Hold	3,741	–	–	﹤0.01%	2412
2016 Q3	$1.56M	Hold	3,741	–	–	﹤0.01%	2406
2016 Q2	$1.75M	Hold	3,741	–	–	﹤0.01%	2406
2016 Q1	$1.93M	Hold	3,741	–	–	﹤0.01%	2394
2015 Q4	$2.94M	Hold	3,741	–	–	﹤0.01%	2337
2015 Q3	$5.13M	Hold	3,741	–	–	﹤0.01%	2163
2015 Q2	$7.51M	Buy	+3,741	New	+$9.55M	﹤0.01%	2127

Other funds holding HTGM

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return

CPA

Cowen Prime Advisors New York $290M AUM 57.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HWM

HighMark Wealth Management St. Paul, Minnesota $299M AUM 53.01% 1-Year Est. Return

First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return

Fidelity Investments's HTGM Position: Q4 2019 in Review

Fidelity Investments sold out of HTG Molecular Diagnostics, Inc. Common Stock (HTGM) in Q4 2019, closing a stake of 14,961 shares — an estimated $1.83M sold.

Fidelity Investments first reported a position in HTGM in Q2 2015 and held it in 18 quarters. The position peaked at $18.1M in Q3 2018. 27 funds tracked by Wall St. Rank hold HTGM as of Q4 2019.

Fidelity Investments reported no remaining HTG Molecular Diagnostics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
Fidelity Investments sold 14,961 HTG Molecular Diagnostics, Inc. Common Stock shares in Q4 2019, an estimated $1.83M.
Fidelity Investments first reported a position in HTG Molecular Diagnostics, Inc. Common Stock in Q2 2015 and held it in 18 quarters.
Fidelity Investments's HTG Molecular Diagnostics, Inc. Common Stock position peaked at $18.1M in Q3 2018.
27 funds tracked by Wall St. Rank held HTG Molecular Diagnostics, Inc. Common Stock as of Q4 2019.

Based on Fidelity Investments's 13F filing for Q4 2019, filed 7 Feb 2020.